Is NADH effective in the treatment of Parkinson's disease?

Drugs and Aging

Volumn 13, Issue 4, 1998, Pages 263-268

  Swerdlow, Russell H ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; TYROSINE 3 MONOOXYGENASE;

BIOSYNTHESIS; CLINICAL TRIAL; CONTROLLED STUDY; DOPAMINE METABOLISM; DRUG EFFICACY; DRUG MECHANISM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; META ANALYSIS; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; REVIEW;

ANTIPARKINSON AGENTS; HUMANS; NAD; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 0031785692     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199813040-00002     Document Type: Review

References (31)

1. McGeer PL, McGeer EG. Enzymes associated with the metabolism of catecholamines, acetylcholine and GABA in human controls and patients with Parkinson's disease and Huntington's chorea. J Neurochem 1976; 26: 65-76
2. Reiderer P, Rausch WD, Birkmayer W, et al. CNS modulation of adrenal tyrosine hydroxylase in Parkinson's disease and metabolic encephalopathies. J Neural Transm 1978; Suppl. 14: 121-31
3. Nagatsu T, Yamaguchi T, Kato T, et al. Biopterin in human brain and urine from controls and parkinsonian patients: application of a new radioimmunoassay. Clin Chim Acta 1981; 109: 305-11
4. Lewitt PA, Miller LP, Newman RP, et al. Tyrosine hydroxylase cofactor (tetrahydrobiopterin) in parkinsonism. In: Hassler RG, Christ JF, editors. Advances in Neurology 40, New York: Raven Press, 1984: 459-62
5. Moore AP, Behan PO, Jacobsen W, et al. Biopterin in Parkinson's disease. J Neurol Neurosug Psychiatry 1987; 50: 85-7
6. Birkmayer W, Birkmayer JGD. Iron, a new aid in the treatment of Parkinson patients. J Neural Transm 1986; 67: 287-92
7. Birkmayer JGD, Birkmayer W. Improvement of disability and akinesia of patients with Parkinson's disease by intravenous iron substitution. Ann Clin Lab Sci 1987; 17: 32-5
8. Lhermitte J, Kraus WM, McAlpine B. On the occurrence of abnormal deposit of iron in the brain in parkinsonism with special reference to its localization. J Neural Psychopath 1924; 5: 1810-2
9. Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 1996; 47 (6 Suppl. 3): S161-170
10. Sengstock GJ, Olanow CW, Menzies RA, et al. Infusion of iron into the rat substantia nigra: nigral pathology and dose-dependent loss of strialal dopaminergic markers. J Neurosci Res 1993; 35: 67-82
11. Dexter DT, Jenner P, Marsden CD. Oxyferrixcorbone elevates the total iron content of blood but not brain. Mov Disord 1989; 4: 176-82
12. Birkmayer GJD, Birkmayer W. Stimulation of endogenous L-dopa biosynthesis: a new principle for the therapy of Parkinson's disease. Acta Neurol Scand 1989; 126: 183-7
13. Birkmayer W, Birkmayer GJD. Nicotinamidadenindinucleotide (NADH): the new approach in the therapy of Parkinson's disease. Ann Clin Lab Sci 1989; 19: 38-43
14. Birkmayer W, Birkmayer GJD, Vrecko K, et al. The coenzyme nicotinamide adenine dinucleotide (NADH) improves the disability of Parkinsonian patients. J Neural Trans (P-D Sect) 1989; 1: 297-302
15. Birkmayer W, Birkmayer JGD, Vrecko K, et al. The clinical benefit of NADH as stimulator of endogenous L-dopa biosynthesis in Parkinsonian patients. In: Korczyn AD, Melamed E, Youdin MBH, editors. Advances in Neurology 53, New York, Raven Press, 1990: 545-9
16. Langston JW, Ballard PA, Tetrud JW, et al. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219: 979-80
17. Forno LS, Langston JW, DeLanney LE, et al. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann Neurol 1986; 20: 449-55
18. Parker WD, Byson SJ, Parks JK. Electron transport chain abnormalities in idiopathic Parkinson's disease. Ann Neurol 1989; 26: 719-23
19. Schapira AHV, Coloper JM, Dexter D, et al. Mitochondrial complex I deficiency in Parkinson's disease [letter]. Lancet 1989; 1: 1289
20. Mizuno Y, Ohta S, Tanaka M, et al. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun 1989; 163: 1450-5
21. Swerdlow RH, Parks JK, Miller SW, et al. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol 1996; 40: 663-71
22. Lawen A, Martinus RD, McMullen GL, et al. The universality of bioenergetic disease: the role of mitochondrial mutation and the putative inter-relationship between mitochondria and plasma membrane NADH oxidoreductase. Mol Aspects Med 1994; 15 Suppl.: S13-27
23. Jenkins BG, Brouillet E, Chen YCI, et al. Non-invasive neurochemical analysis of focal excitotoxic lesions in models of neurodegenerative illness using spectroscopic imaging. J Cereb Blood Flow Metab 1996; 16: 450-61
24. Bender DA, Earl CJ, Lees AJ. Niacin depletion in Parkinsonian patients treated with L-dopa, benserazide and carbidopa. Clin Sci 1979; 56: 89-93
25. Birkmeyer JGD, Vrecko C, Vole D, et al. Nicotinamide adenine dinucleotide (NADH): a new therapeutic approach to Parkinson's disease. Acta Neurol Scand 1993; 146: 32-5
26. Vrecko K, Birkmayer JG, Krainz J. Stimulation of dopamine biosynthesis in cultured PC 12 phaeochromocytoma cells by the coenzyme nicotinamide adeninedinucleotide (NADH). J Neural Transm Park Dis Dement Sect 1993; 5: 147-56
27. Shoffner JM, Watts RL, Juncos JL, et al. Mitochondrial oxidative phosphorylation defects in Parkinson's disease. Ann Neurol 1991; 30: 332-9
28. Dizdar N, Kagedal B, Lindvall B. Treatment of Parkinson's disease with NADH. Acta Neurol Scand 1994; 90: 345-7
29. Kuhn W, Muller T, Winkel R, et al. Parenteral application of NADH in Parkinson's disease: clinical improvement partially due to stimulation of endogenous levodopa biosynthesis. J Neural Transm 1996; 103: 1187-93
30. Birkmayer W, Birkmayer JGD, Vrecko C, et al. Nicotinamide adenine dinucleotide (NADH) as medication for Parkinson's disease: experience with 415 patients. New Trends Clin Neuropharm 1990; 4: 7-24
31. Birkmayer W, Neumayr E. Die moderne medikamentose behandlung des Parkinsonismus. Z Neurol 1972; 202: 257-80